TFs have been historically considered “undruggable”, however, recent advances in technologies shed new light on the TF-targeting strategies, as a part of targeted drug discovery and a number of TF specific drugs are in clinical trials for cancer diseases [112–114]. The gene discussed is TF; the disease is cancer.